Reflection- Therapeutic Industry
INTRODUCTION TO THE THERAPEUTICS INDUSTRY
The Master of Pharmaceutical Medicine program at the University of New South Wales went with many engagements on the number of activities that prepare a way for my studies in next semester two. As usual, the first day began with induction in my view as part of the university actions, informing students with processes and systems in pursuing the course while at the university. The induction processes at some stage prepare me to understand the University of New South Wales systems and procedures relevant to the Master of Pharmaceutical Medicine. It helps me settle down quickly in the new environment, which gives a sense of belonging and enthusiasm.
In the first week, as part of an assessment task or
activities for the rest of the semester. We expected to complete the class
introduction. It was fascinated to learn that the degree course has attracted
many fellow students from various diverse cultural, socioeconomic, and
professional backgrounds. My dedication was to study the chosen course relevant
and essential, given my education backgrounds in Public Health and Clinical
Epidemiology. The first concluded with downloading and reviewing of course
outline and timetable. It was not hard
to explore the new online learning environment from the University of New South
Wales, including blackboard, update calendar and review booklet to the start
course ensuring to familiarise myself with the course assessment undertakings.
The first week was extraordinary in many aspects, not only preparation and
familiarity with the course but also an introduction to week two, especially
when we began our first session on the Milestones in pharmaceutical product
development. Part of the importance of week two was contacting and meeting my
group members, made some introduction and began to discuss tasks at hand. We
fronted with challenges of being new to each other at different locations at a
time when the Coronavirus was dominating headlines in Wuhan, China and at the
global crossing points. In my first contact through email demonstrate the
reality that some of the team members got stranded in China, but willing to
continue with the course working while overseas. One would not wonder why a
student (s) would take courage to study while overseas, despite that critical
time. Perhaps, this might be interpreted in different ways, but in my
assumption, it was a commitment that they would accomplish the course of their
desire. Taking the lead was part of the teamwork, networking, cooperation, and
collaboration, which is part of course attributes, learning professional ethics
and cooperation. Unfortunately,
unforeseen circumstances emerged, one of our team members in the group dropped
out of the semester, affected the allocation of our tasks for assessment. We
once again presented with challenges which we must mitigate. Nonetheless, the
part of the task assigned to the student was taken over by us in the group,
although, it had added to the existing loads.
We proceeded to week three with the burden of emerging the coronavirus that has almost affect every university and pharma industries in
Australia, especially mode of face to face delivery learning. Fortuitously, we
were lucky that our course designed online interaction that overcomes the new
challenges of 21st Century learning, including impediment of
Coronavirus (COVID-19). At the state of
COVID-19 confusion, not only we were at the verge of completing Draft Wiki
outline, part of an assessment task 1 due on 11th March 2020. But also
completing discussion forum entries and ELISE tutorial. My contribution was to
select the topic of our assessment and introduce it to our team members. At
first, not all the members of the team responded. Differently, we had a
different approach to a diverse learning environment and the people. But, at a
later stage, the group agreed to the topic selected, storm the work with
enthusiasm and desire to complete the first part of the assessment task in that
point in time.
For example, COVID-19 was challenging aspect or barrier to
the learning and major pharma companies at a time. Challenges like COVID-19
bear the consequences on the pharma industries production at a large scale. As
we were proceeding with week two learning on Milestones in Pharmaceutical
Product Development. In my observation, Professor, Orin`s first presentation as
I quoted, “ the development of new drug may reward the pharmaceutical industry for
making a large gain, there are also hurdles involved which make pharma
industries lose a great amount of money.” These issues of gain and losses are
realised in the process of testing drug safety, efficacy, and efficiency to
determine approval of new medicine/drugs. Besides, Professor Peter Gunning
indicated in his lectures about the fundamental of academic research to
discover and develop potential modern prescription/medicine for the disease. In
my presentation and submission on the discussion forums, suggested an
“innovation partnership in drug discovery, development and funding” to be crucial
to the pharma industries. This
discussion reinforced the part of ideas discussed on Pharmaceutical Medicine,
20th Anniversary Symposium addressing enablers and barriers in the development
of new drug/medicine. My conclusion on facilitators and barriers included
decades of effort of expenditures and partnership, the heavy burden of finances
and forging a strong alliance with interested partners. The above presentations
influence me to put more interest and hard work in the assessment task 2, the
current and future driver for therapeutic industries mostly dependent on the
socio-cultural environment, technology environment and legal partnership. For
example, at the socio-cultural climate today, the nations around are wrestling
with COVID-19 pandemic posing contraction other industries ad sectors of the
economy. The pharmaceutical industry expected to grow at more than 5.8 per cent[1]. Also, the key to future trends and
growth in the sector include changes in consumer attitudes, online patient
community, government and insurance company policies, disease prevalence, and
AI partnership with big data[2]. Besides, at my workplace, supplying
pharmacy support services to isolated and vulnerable communities such as paying
for prescriptions have tended out more expensive in this time of COVID-19
pandemic.
Apart from COVID-19 challenges, many more encounters emerged,
including the murder of my beloved cousin, who we shared accommodation. The
death of a cousin has affected my psychological wellbeing, inflicted stress,
and trauma, thus, almost affect me to drop out of the course. The intervention
at the University of New South Wales, Department of Master of Pharmaceutical
Medicine especially Professor Orin granting me an extension strengthen my
morale to continue with the course to and be able to complete my assessments.
March 2020 was one of the worst month experience in my life with lockdown and
working online introduced by the workplaces. My daily work involved despatching
care package, including prescript medicines/drugs to unable clients during
COVID-19 pandemic. The work at this time of epidemic inflicted more fear and
anxiety for a possible contraction of COVID-19, although, we almost wear
protective equipment.
Interestingly as we were continuing with learning in week
four, we found ourselves providing feedback as colleagues and team in the group
assessment. In the assessment review, my work was focusing on how much each
team members contributed to the evaluation. The evaluation was guided through
the rubric to self-evaluate and evaluate my colleagues` work. One thing that
was quite challenging is awarding marks to individual students. During
assessing other students work, my emphasis on self-assessing was to reflect,
critique, judge critically and ultimately form opinions to other student work.
Some of the critical observations observed through peer assessment include the
ability to give a better or less judgement to my fellow students and reflection
through my work. On the other hands, there were doubts about the ability of
other students whether they could provide reliable, fair, and conclusive
results (grades) to other student assessments.
Looking at the rest of the course models, in my view was a
tremendous undertaking to have learnt throughout the current status of the
global therapeutic industry, history and structure, future strategies for
therapeutics industry, the role of therapeutics in improving health outcomes
and pharma ethics. In these sessions above, it was great to meet different
pharma professionals from various industry providing lectures and supporting
learning. Their talks reinforced my feedbacks online discussions. The online
forums informed my discussions presentations to other students through
critically analysing the work of others. Some of forum discussion topics selected
for the assessment include Innovation Partnerships in Drug discovery,
development, and funding, Investment in the Electric Production of Heat and
Medical Technology and Pharmaceuticals.
These topics were so crucial in the present and future
pharmaceutical industry. Innovation partnership in drug discovery, development,
and funding future pharma industry sustainability new emerging world order is
essential. It is worth mentioning that the price of the development of drugs or
medicine is highly increasing around reimbursement agencies and healthcare
providers. Indicated that high cost for new drug development could appear in the
healthcare budget pending on the ever-increasing pressures. Pharma industries
must invest in climate policy reduction of carbon dioxide (CO2) for
transparency in the climate change commitment and accountability.
The knowledge that gained in this semester one has been
relevant to me, especially in the healthcare sector. The support for pharmacy
prescription services to the vulnerable and isolated communities’ population in
Collingwood is one of the areas of my work. It is an area of learning-
pharmaceutical medicine to continue to gain more knowledge for future work and
self-development.
Although there were hurdles faced during the semester, it is
within my plan prerequisite to ensure that these hurdles are actioned upon as
they come through. Time management, though, during the time of mourning, must
be mitigated in a better way for successful completion in Master of
Pharmaceutical Medicine.
Reference:
1. Lou, B., & Wu, L.,. Artificial Intelligence and Drug
Innovation: A large scale examination of the pharmaceutical industry. 2020;
Available from: <https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3524985>.
2. Szmelter, A., Global pharmaceutical industry:
characteristics and trends. In Global Supply Chains in the Pharmaceutical
Industry. IGI Global, 2019: p. 57-85.
Comments
Post a Comment